The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy
Antibiotics · 27.05.2023 · 12 (6) · 971
DOI: 10.3390/antibiotics12060971 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 27.05.2023. Verfasst von Antonio Anastasia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro", University of Palermo, 90127 Paler…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VQR improvement assigned to the Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties of the University of Palermo.
Abstract (Originalsprache)
Fosfomycin in intravenous (IV) formulation has re-emerged as a valuable tool in the treatment of multi-drug resistant (MDR) and extensively drug-resistant (XDR) infections because of its broad spectrum of antibacterial action and pharmacokinetic characteristics. This retrospective study aimed to evaluate how fosfomycin was used in patients admitted to the Polyclinic of Palermo between January 2017 and July 2022. Clinical indications, therapeutic associations, clinical outcomes, and any side effects were analyzed. Intravenous fosfomycin was used in 343 patients, 63% male, with a mean age of 68 years (range 15–95). Urinary tract infections (UTIs) and hospital-acquired pneumonia (HAP) were the main indications for treatment (19% and 18% of the total cases, respectively), followed by skin and soft tissue infections and sepsis. IV fosfomycin was administered in combination with other antibacterial agents, the most common of which were ceftazidime/avibactam (35%), meropenem (17%), and colistin (14%). Nineteen patients received it as monotherapy for UTIs. About 66% had resolution of the infectious process with clinical remission (cure or discharge). Electrolyte disturbances occurred in 2.6% and gastrointestinal symptoms occurred in 2.9%. The data showed that IV fosfomycin is a safe and effective therapeutic option in the treatment of infections with multidrug-resistant microorganisms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro", University of Palermo, 90127 Palermo, Italy.
- Infectious and Tropical Disease Unit and Sicilian Regional Reference Center for the Fight against AIDS, AOU Policlinico "P. Giaccone", 90127 Palermo, Italy.
- Antimicrobial Stewardship Team, AOU Policlinico "P. Giaccone", 90127 Palermo, Italy.
- Microbiology and Virology Unit, AOU Policlinico "P. Giaccone", 90127 Palermo, Italy.
- UOC Farmacia, AOU Policlinico "P. Giaccone", 90127 Palermo, Italy.
ORCID-Profile: Giovanni Maurizio Giammanco, Antonio Cascio
Förderung
- VQR improvement assigned to the Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties of the University of Palermo
Zitieren
APA
Anastasia, A., Bonura, S., Rubino, R., Giammanco, G. M., Miccichè, I., Di Pace, M. R., Colomba, C., & Cascio, A. (2023). The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy. Antibiotics, 12(6), 971. https://doi.org/10.3390/antibiotics12060971
Vancouver
Anastasia A, Bonura S, Rubino R, Giammanco GM, Miccichè I, Di Pace MR, et al. The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy. Antibiotics. 2023;12(6):971. doi:10.3390/antibiotics12060971
BibTeX
@article{Anastasia2023,
author = {Anastasia, Antonio and Bonura, Silvia and Rubino, Raffaella and Giammanco, Giovanni Maurizio and Miccichè, Irene and Di Pace, Maria Rita and Colomba, Claudia and Cascio, Antonio},
title = {The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy},
journal = {Antibiotics},
year = {2023},
volume = {12},
number = {6},
pages = {971},
doi = {10.3390/antibiotics12060971}
}
EUVIMED